Latest Manufacturing Processes News

Titomic Limited has entered a strategic teaming agreement with REPKON USA to jointly develop and apply its kinetic fusion cold spray technology for advanced defense manufacturing, focusing on repairs and performance enhancements of critical military assets.

Green Critical Minerals has announced a major breakthrough with its VHD Graphite technology, delivering thermal diffusivity far surpassing copper and aluminium, promising a revolution in AI and high-performance electronics cooling.

AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

First Graphene has secured an additional AUD$404,300 R&D tax rebate for significant manufacturing process improvements at its Henderson facility, complementing a recent AUD$166,000 rebate from UK-based research efforts.

EBR Systems has signed a long-term lease for a 51,000 sq ft facility in Santa Clara, California, positioning itself for significant manufacturing expansion and future growth in wireless cardiac pacing technology.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

4DS Memory Limited has completed critical testing on its Fifth Platform Lot, paving the way for manufacturing a 20nm memory cell array in the upcoming Sixth Platform Lot. This milestone could position 4DS’s ReRAM technology as a next-generation memory solution.

EBR Systems has announced a rescheduling of the FDA Pre-Approval Inspection for its wireless cardiac pacing device to January 14, 2025, while maintaining its regulatory approval timeline for Q1 2025 and a commercial launch later in the year.